BRCA1 and neoplasm: The most common mechanisms of PARPi sensitivity of a BRCA1/2-deficient tumor are through synthetic lethality and PARP trapping (2, 28), but others include the enhancement of c-NHEJ and the inhibition of alternative NHEJ (22, 29, 30).